

REMEDI PHARMACIES LIMITED
Abridged Unaudited Financial Statements
for the financial year ended 31 December 2025

REMEDI PHARMACIES LIMITED
Abridged Unaudited Financial Statements
for the financial year ended 31 December 2025

Contents

Statement of Financial Position	2
Statement of Changes in Equity	3
Notes to the Abridged Financial Statements	4

STATEMENT OF FINANCIAL POSITION

As at 31 December 2025

	Note	2025 €	2024 €
Fixed assets			
Investments	3	10	10
		10	10
Creditors: amounts falling due within one year		(6,291)	(5,271)
Net current liabilities		(6,291)	(5,271)
Total assets less current liabilities		(6,281)	(5,261)
Net liabilities		(6,281)	(5,261)
Capital and reserves			
Called-up share capital	4	66	66
Profit and loss account		(6,347)	(5,327)
Total shareholder's deficit		(6,281)	(5,261)

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with Financial Reporting Standard 102 'The Financial Statement Reporting Standard applicable in the UK and Republic of Ireland' as adapted by Section 1A of FRS 102 and the Companies Act 2014.

We, as directors of Remedi Pharmacies Limited state that:

- The Company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- The Company is availing itself of the exemption on the grounds that the conditions specified in s.358 are satisfied;
- The shareholders of the Company have not served a notice on the Company under s.334(1) in accordance with s.334(2);
- We acknowledge the Company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the Company at the end of its financial year and of its profit or loss for such a year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the Company;
- The Company has relied on the specified exemption contained in s.352 Companies Act 2014; and has done so on the grounds that the Company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with s.353 Companies Act 2014.

The financial statements of Remedi Pharmacies Limited (registered number: 350431) were approved and authorised for issue by the Board of Directors on 13 March 2026. They were signed on its behalf by:

Juan del Alamo

Juan Jose Del Alamo
Director

Juan Jose Del Alamo Guitierrez

Juan Jose Del Alamo Guitierrez
Director

STATEMENT OF CHANGES IN EQUITY
for the financial year ended 31 December 2025

	Called-up share capital	Profit and loss account	Total
	€	€	€
At 01 January 2024	66	(4,077)	(4,011)
Loss for the financial year	-	(1,250)	(1,250)
Total comprehensive loss	-	(1,250)	(1,250)
At 31 December 2024	66	(5,327)	(5,261)
At 01 January 2025	66	(5,327)	(5,261)
Loss for the financial year	-	(1,020)	(1,020)
Total comprehensive loss	-	(1,020)	(1,020)
At 31 December 2025	66	(6,347)	(6,281)

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 31 December 2025

1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Remedy Pharmacies Limited (registered number 350431) (the Company) is a private company, limited by shares, registered in Ireland under the Companies Act 2014. The address of the registered office is Unit 8, Customs House Square, IFSC, Dublin 1, Ireland. The nature of the Company's operations and its principal activities are set out in the Directors' Report.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and comply with the financial reporting standards of the Financial Reporting Council including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") as adapted by Section 1A of FRS 102 and the Companies Act 2014.

The functional currency of Remedy Pharmacies Limited is considered to be EUR because that is the currency of the primary economic environment in which the Company operates.

These financial statements are separate financial statements.

Going concern

The directors have assessed the Statement of Financial Position and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Consolidation exemption

The company is exempt from preparing group financial statements per section 297 of the Companies Act 2014 as the size of the group is below the threshold in both the current and preceding years.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Statement of Financial Position date. If there is objective evidence of impairment, an impairment loss is recognised in the Income Statement as described below.

Fixed asset investments

Investments are recognised initially at fair value which is normally the transaction price excluding transaction costs. Subsequently, they are measured at fair value through profit or loss if the shares are publicly traded or their fair value can otherwise be measured reliably. Other investments are measured at cost less impairment.

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS (continued)
for the financial year ended 31 December 2025

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Financial assets are derecognised when and only when the contractual rights to the cash flows from the financial asset expire or are settled, or the Company transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or the Company, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Financial liabilities are derecognised when the company's contractual obligations expire or are discharged or cancelled.

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS (continued)
for the financial year ended 31 December 2025

Ordinary share capital

The ordinary share capital of the Company is presented as equity.

2. Employees

	2025	2024
	Number	Number
Monthly average number of persons employed by the Company during the year, including directors	-	-

3. Fixed asset investments

Investments in subsidiaries

	2025	2024
	€	€
Cost		
At the beginning of financial year	10	10
At the end of financial year	10	10
Carrying value at the end of financial year	10	10

Investments in shares

Name of entity	Registered office	Principal activity	Class of shares	Ownership 31.12.2025	Ownership 31.12.2024
IFSC Pharmacy Limited	Ireland	Retail pharmacy	Ordinary	100.00%	100.00%

The capital and reserves and the loss of the subsidiary undertaking was as follows:

	Capital and reserves at 2025	Loss for the year ended 2025
	€	€
IFSC Pharmacy Limited	1,646,358	(506)

4. Called-up share capital

	2025	2024
	€	€
Allotted, called-up and fully-paid		
6,500 Ordinary Shares Class 1 shares of €0.01 each	65	65
1 Redeemable 'A' Ordinary Shares share of €1.00	1	1
	66	66

5. Financial commitments

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS (continued)
for the financial year ended 31 December 2025

The Company had no material capital commitments at the year ended 31 December 2025.

6. Related party transactions

The Company has availed of the exemption provided in FRS 102 Section 33 Related Party Disclosures not to disclose transactions entered into with fellow group companies that are wholly owned within the group of companies of which the Company is a wholly owned member.

The directors of the Company are deemed to be the key personnel of the Company as defined in Section 33 of FRS 102. No directors' remuneration was paid during the current or previous year.

7. Events after the Balance Sheet date

There have been no events after the balance sheet date affecting the Company since the financial year.

8. Ultimate controlling party

The company is controlled by Juan Jose Del Alamo Iborra, a director of the company, and a director and majority shareholder of Del Alamo Holdings Limited, the ultimate parent company.